A 54-year-old comes in after a routine low-dose CT screening (LDCT) scan. Seven-millimeter nodule, right lower lobe, outer third of the lung. Stage IA five-year survival exceeds 80 percent. You want tissue now, before this advances.

The navigation platform is excellent. It puts the bronchoscope precisely where the CT says the nodule is. You reach generation six of the bronchial tree. The nodule is in generation nine. The airway ahead narrows to below two millimeters. The scope is 3.5 millimeters at the tip.

You stop.

You order a CT-guided percutaneous biopsy — a separate appointment, radiation exposure, and a pneumothorax risk between 15 and 25 percent depending on the series you read. Some patients accept it. Some don't come back. Some get diagnosed at Stage III instead.

The navigation worked perfectly. The access did not exist.

What the Published Data Actually Shows

I want to be precise about where robotic bronchoscopy stands, because the platforms do not deserve a blanket dismissal. Intuitive's Ion and J&J's Monarch have meaningfully improved outcomes for accessible peripheral lesions. A 2024 meta-analysis of ten robotic bronchoscopy studies covering 724 lesions found pooled diagnostic yield at 80.4 percent overall. Ion's platform has shown up to 88 percent yield in published studies. That is real progress.

[Patel PP, et al. Frontiers in Oncology. 2025.]

The problem is what those numbers exclude.

As noted in a 2025 Frontiers in Surgery meta-analysis, diagnostic yield for peripheral lesions under two centimeters drops to 34 percent with conventional guided bronchoscopy. One in three patients. Those sub-two-centimeter peripheral nodules are precisely what LDCT screening is now finding in the greatest numbers — and they are the ones that matter most for early-stage detection.

[Frontiers in Surgery meta-analysis. 2025. doi:10.3389/fsurg.2025.1566902]

The BENEFIT study — the first prospective multicenter trial of robotic bronchoscopy in live human subjects — enrolled 54 patients with peripheral lesions between one and five centimeters. Navigation success hit 96.2 percent. Overall diagnostic yield did not exceed 67 percent. Perfect navigation. The access constraint remained.

[Fielding D, et al. Chest. 2019;155(3):609-618.]

None of this reflects poorly on the engineering of these platforms. It reflects a physical constraint that the current design architecture imposes, regardless of how sophisticated the navigation becomes.

Why the Scope Stops Where It Does

Every current bronchoscope places a camera sensor at the working tip. That sensor requires wiring, thermal management, and a housing with a minimum outer diameter set by the packaging around the sensor itself. The practical floor across commercial platforms today is 2.0 to 4.2 millimeters at the working tip.

The peripheral bronchi narrow continuously beyond generation six — from approximately two millimeters down toward one millimeter and below. The scope runs out of airway. This is not a software problem. It is not a navigation algorithm problem. It is a geometry problem, and adding imaging adjuncts at the procedure site does not change it.

The most advanced programs are now pairing robotic bronchoscopy with intraoperative CT imaging during the procedure. Work presented at the 2025 European Respiratory Society Congress showed strong diagnostic results with this combination — including for very small lesions. Excellent progress. Still bounded by the same access ceiling. Intraoperative imaging confirms what the scope finds at the lesion site. It does not help the scope reach a site that is physically inaccessible.

[Steinack C, et al. ERS International Congress. September 2025.]

Three to four bronchial generations of additional depth. That is not incremental — it is access to an anatomical zone that no commercial bronchoscope has ever reliably reached with real-time imaging.

The Screening Expansion Made This More Urgent

The 2021 update to US Preventive Services Task Force guidelines lowered the lung cancer screening eligibility age from 55 to 50 and reduced the required smoking history from 30 to 20 pack-years. As reported in JAMA, this change is projected to nearly double the eligible screening population and increase lung cancer mortality reduction from 9.8 to 13 percent.

[USPSTF. "Screening for Lung Cancer." JAMA. 2021;325(10):962-970.]

More patients screened means more peripheral nodules found, more of them small, more of them in the outer third of the lung. That 3.2 percentage point mortality improvement depends entirely on the ability to biopsy what the CT scan finds. For deep peripheral lesions, that assumption still fails in a third of cases.

The detection capability expanded. The biopsy access did not. That mismatch is growing.

What VerAvanti's Investigational Endoscope Is Designed to Do

VerAvanti's investigational 1mm endoscope removes the camera sensor from the working tip entirely. The imaging is done through a single optical fiber that scans the tissue in a spiral pattern, with all the electronics kept outside the patient. Nothing at the tip except the fiber itself.

No sensor at the tip means no minimum outer diameter set by sensor packaging. At approximately 1mm outer diameter, the investigational endoscope may be able to follow the airway into the bronchial generations where current bronchoscopes stop — providing direct forward-viewing visualization at the lesion site rather than stopping several generations short.

The technology has its roots in more than two decades of research at the University of Washington's Human Photonics Lab. The physics are established. The current engineering work targets the specific anatomy of peripheral bronchoscopy access.

VerAvanti's investigational endoscope has not received FDA clearance. All capability statements are subject to clinical validation and regulatory review.

Why I Am Here

I am not a pulmonologist. I have spent 35 years investing across technology sectors — not healthcare specifically, but large markets where a genuine breakthrough changes how people live. The pattern I look for is a structural problem with a specific, addressable cause that has gone unsolved long enough that the human cost becomes undeniable.

Lung cancer kills 125,000 Americans a year. The detection gap in peripheral bronchoscopy is structural, not incidental. Generations 7 through 12 of the bronchial tree have been physically out of reach for every commercial bronchoscope ever built — not because of navigation, but because the working tip has always been too large to follow the airway.

That is a solvable problem.

If you are an interventional pulmonologist or thoracic surgeon who has encountered the access wall in your own practice, I want to hear about the specific cases. Reach out directly.

Key References

1. Patel PP, et al. "Robotic-assisted lung nodule diagnosis and resection." Frontiers in Oncology. 2025.

2. Frontiers in Surgery meta-analysis of guided bronchoscopy diagnostic yield. 2025. doi:10.3389/fsurg.2025.1566902

3. Fielding D, et al. "Robotic Bronchoscopy for Peripheral Pulmonary Lesions (BENEFIT)." Chest. 2019;155(3):609-618.

4. Steinack C, et al. Robotic bronchoscopy with intraoperative CT imaging. ERS International Congress. September 2025.

5. USPSTF. "Screening for Lung Cancer." JAMA. 2021;325(10):962-970.

6. American Lung Association. USPSTF Lung Cancer Screening Recommendation Toolkit. lung.org.